Global AI-Powered Embryo Selection Market Size, Share, and COVID-19 Impact Analysis, By Product Type (AI Imaging & Scoring Platforms, AI Embryo Selection Software, IVF Lab Automation Systems with AI, AI Predictive Analytics & Data Tools, and Support Modules / Integration Solutions), By Application (In Vitro Fertilization (IVF), Cryopreservation & Embryo Storage, Research & Clinical Trials, and Embryo Monitoring & Morphokinetic Analysis), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035.

Global AI-Powered Embryo Selection Market Insights Forecasts to 2035

• The Global AI-Powered Embryo Selection Market Size Was Estimated at USD 165.10 million in 2024
• The Market Size is Expected to Grow at a CAGR of around 11.05% from 2025 to 2035
• The Worldwide AI-Powered Embryo Selection Market Size is Expected to Reach USD 522.70 million by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, the global AI-powered embryo selection market size was worth around USD 165.10 million in 2024 and is predicted to grow to around USD 522.70 million by 2035 with a compound annual growth rate (CAGR) of 11.05% from 2025 to 2035. The market for AI-powered embryo selection offers opportunities for increased IVF success rates, better predictive accuracy, individualized reproductive decision-making, decreased clinical variability, operational efficiency, increased access to international fertility services, and quicker uptake of cutting-edge reproductive technologies.

Market Overview

The assisted reproductive technology (ART) industry, the AI-powered embryo selection market, is a specialized area that uses artificial intelligence (AI) algorithms to examine time-lapse images, morphological characteristics, and genetic markers of embryos produced via in vitro fertilization (IVF). Compared to traditional morphological evaluations, this market enables non-invasive, data-driven identification of viable embryos with superior implantation potential, increasing IVF success rates by 15–20%. For Instance, in September 2025, Fairtility debuted its FDA-cleared CHLOE platform for AI embryo grading, while Alife Health launched CE Mark–certified Embryo Predict, boosting clinical usage and expanding transatlantic reproductive technology access dramatically. Growing demand for assisted reproductive technologies, rising IVF procedure volumes worldwide, and the use of AI in clinical embryology workflows all contribute to the growth of the AI-powered embryo selection market.  The application of AI in reproductive health is further fostered by government programs and partnerships between tech businesses and medical professionals

.  

Report Coverage

This research report categorizes the AI-powered embryo selection market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the AI-powered embryo selection market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the AI-powered embryo selection market.   

Driving Factors  

The AI-powered embryos selection market is growing as fertility clinics and embryologists rely on AI for better in-vitro fertilization (IVF) accuracy and effectiveness, thus increasing the number of successful cases. The growth is driven by the rise in infertility rates, the postponement of motherhood, and fertility problems due to lifestyle changes, which make it hard for a clinic to improve patient outcomes during limited treatment cycles. Technological advances, mainly the development of exact algorithms that lower the backend grading subjectivity by 15-25%, are not only helping the adoption of the process but also making it more attractive in a scenario of the slow generational trend.

Restraining Factors  

The market for AI-driven embryo selection faces constraints due to strict regulatory oversight, ethical issues surrounding algorithmic reproductive choices, lack of data standardization, significant implementation expenses, interoperability obstacles, clinician reluctance, privacy threats, and the requirement for comprehensive clinical validation to secure safety, dependability, and fair patient 

Market Segmentation     

The AI-powered embryo selection market share is classified into product type and application.     

• The AI imaging & scoring platforms segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.        

Based on the product type, the AI-powered embryo selection market is divided AI imaging & scoring platforms, AI embryo selection software, IVF lab automation systems with AI, AI predictive analytics & data tools, and support modules/integration solutions. Among these, the AI imaging & scoring platforms segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. AI Imaging & Scoring Platforms is driven by deep learning algorithms, high-resolution time-lapse imaging, and automated scoring systems that increase embryo morphology assessment and IVF success. The potential of AI imaging and scoring systems to increase the accuracy of embryo assessments, decrease subjectivity, and raise the success rates of in vitro fertilization (IVF) is what motivates research.

• The in vitro fertilization segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.       

Based on the application, the AI-powered embryo selection market is divided into in vitro fertilization (IVF), cryopreservation & embryo storage, research & clinical trials, and embryo monitoring & morphokinetic analysis. Among these, the in vitro fertilization segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The In Vitro Fertilization (IVF) industry is driven by the integration of better imaging and scoring platforms to improve embryo grading, implantation prediction, and cycle success. IVF facilities rely on software-based assessments to eliminate subjectivity, standardize decisions, and optimize pregnancy outcomes.

Regional Segment Analysis of the AI-Powered Embryo Selection Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the AI-powered embryo selection market over the predicted timeframe.   

North America is anticipated to hold the largest share of the AI-powered embryo selection market over the predicted timeframe. North America's strong technical environment and highly developed healthcare infrastructure are the main factors fostering innovation in assisted reproductive technologies. The U.S. Centers for Disease Control and Prevention (CDC) has reported that the number of IVF cycles in 2022 accounts for 389,993, which indicates a rise of 6% as compared to last year. The year 2024 has begun with the trend of IVF being still on the rise, even though the country’s fertility rate has fallen to 1.6 births per woman; infertility is becoming more widespread, affecting about 13.8% of women of reproductive age (15 to 44 years). Hamilton Thorne Ltd. launched EmbryoView Pro in July 2024, a product that incorporates Artificial Intelligence (AI) for embryo evaluation instantly while minimizing human error at the same time

Asia Pacific is expected to grow at a rapid CAGR in the AI-powered embryo selection market during the forecast period. Asia Pacific is undeniably advantageous due to various factors like the increasing infertility rates, the wider availability of assisted reproductive treatments, and the trend of new fertility infrastructure investments. The countries of China, India, Japan, and South Korea are experiencing a massive increase in IVF procedures, mainly due to changing lifestyle habits, postponing parenthood, and the opening up of more people to reproductive health optionsIndia presents a large market that is growing at a rate of 11.3% CAGR until 2035, which is supported by the expansion of IVF services to over 350,000 treatment cycles annually, increased awareness of embryo viability assessment, and hence higher pregnancy rates, among other factors.

Competitive Analysis:   

The report offers the appropriate analysis of the key organizations/companies involved within the AI-powered embryo selection market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

List of Key Companies

• AIVF Ltd.
• DeepLife AI
• Esco Lifesciences
• Fairtility Ltd.
• FertiliTech
• Merck KGaA
• OvaScience / CooperSurgical
• TMRW Life Sciences
• Vitrolife AB
• Others  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In October 2025, Hanahealth launched the AI-powered embryo assessment tool, Vita Embryo, in partnership with South Korea’s Kai Health, introducing it to IVF labs across India to enhance selection accuracy and treatment outcomes.
• In October 2025, Alife Health announced that its AI-powered Embryo Predict software received CE Mark certification under MDR, enabling marketing across European fertility clinics and supporting embryologists in selecting optimal embryos for transfer.
• In August 2025, Nova IVF Fertility launched AI integration in its labs, introducing Vita Embryo across 120 clinics in 65 cities, enhancing precision and reliability in embryo selection for fertility treatments.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the AI-powered embryo selection market based on the below-mentioned segments:     

Global AI-Powered Embryo Selection Market, By Product Type

• AI Imaging & Scoring Platforms
• AI Embryo Selection Software
• IVF Lab Automation Systems with AI
• AI Predictive Analytics & Data Tools
• Support Modules / Integration Solutions

Global AI-Powered Embryo Selection Market, By Application

• In Vitro Fertilization (IVF)
• Cryopreservation & Embryo Storage
• Research & Clinical Trials
• Embryo Monitoring & Morphokinetic Analysis

Global AI-Powered Embryo Selection Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa